🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

BRIEF-Medical Developments updates on regulatory & marketing approval

Published 28/10/2015, 12:08 pm
© Reuters.  BRIEF-Medical Developments updates on regulatory & marketing approval
MVP
-

Oct 27 (Reuters) - Medical Developments International Ltd MVP.AX :

* Penthrox receives regulatory & marketing approval in the UK

* Says MVP expects first sales to be in January 2016 for penthrox

* "Expect sales to commence in France and Belgium during H2 FY16 once approval in France is granted"

* Licensing and supply agreement with MVP

* "Once approval from France is receipted Mundipharma will pay MVP a further milestone payment of USD $3MLN"

* Mhra approval means galen will pay mvp another milestone payment of GBP £450,000, MVP will receive this in 1H FY 2016

* "Expect significant sales to be made in 2h FY 2016 and beyond" for penthrox

Source text for Eikon ID:nASX1NF792

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.